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The  combination  of  recombinant  protein  antigens  with  an immunostimulator  has  the  potential  to greatly
increase  the  immunogenicity  of recombinant  protein  antigens.  In the  present  study,  we  selected  the
dengue-4  envelope  protein  domain  III  as a dengue  vaccine  candidate  and  expressed  the  protein  in lipi-
dated  form  using  an  Escherichia  coli-based  system.  The  recombinant  lipidated  dengue-4  envelope  protein
domain  III folded  into  the  proper  conformation  and  competed  with  the dengue-4  virus  for  cellular  binding
sites.  Mice  immunized  with  lipidated  dengue-4  envelope  protein  domain  III without  exogenous  adjuvantengue virus
nvelope protein domain III
ipoprotein
accine
had  higher  frequencies  of  dengue-4  envelope  protein  domain  III-speciﬁc  B cells  secreting  antibodies  than
mice  immunized  with  the nonlipidated  form.  Importantly,  lipidated  dengue-4  envelope  protein  domain
III-immunized  mice  demonstrated  a  durable  neutralizing  antibody  response  and had  reduced  viremia
levels  after  challenge.  The  study  demonstrates  that  lipidated  dengue-4  envelope  protein  domain  III is
immunogenic  and  may  be a potential  dengue  vaccine  candidate.  Furthermore,  the  lipidation  strategy  can
pes  o
 201be  applied  to other  seroty
©
. Introduction
Dengue virus is transmitted by mosquitoes, and infection causes
engue fever or severe dengue hemorrhagic fever and dengue
hock syndrome. These diseases are important arthropod-borne
iral diseases [1]. Dengue occurs in more than 120 countries
hroughout tropical and subtropical areas [2]. The growing public
ealth threat of dengue is supported by its wide-spread pres-
nce and increasing number of cases. According to estimates,
here are 390 million dengue infections per year [3]. It is gen-
rally accepted that vaccination is a cost-effective strategy to
ght infectious diseases. However, the complex interaction of 4
Abbreviations: D4ED III, dengue-4 envelope protein domain III; ED III, envelope
rotein  domain III; FFUs, focus-forming units; FRNT, focus reduction neutralization
ests;  LD4ED III, lipidated D4ED III.
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serotypes of dengue virus with the immune system has compli-
cated the development of an effective vaccine. Consequently, a
licensed dengue vaccine is not currently available. Several vac-
cine candidates using different approaches are being assessed in
clinical studies [4]. These approaches include using live attenuated
virus [5,6], live chimeric virus [7,8], subunit vaccines [9], and DNA
vaccines [10,11]. The most advanced dengue vaccine candidate is
Sanoﬁ Pasteur’s live chimeric virus vaccine [12]. A phase 2b study
of this tetravalent dengue vaccine in Thai schoolchildren has been
completed [8]. The results obtained from this study were disap-
pointing because the overall efﬁcacy of the vaccine candidate was
low, at 30.2%. Thus, further efforts are required to develop dengue
vaccines.
Dengue envelope protein domain III (ED III) folds independently
and is accessible and exposed on the virion surface. It has been
demonstrated that ED III is the critical region for viral attachment to
cellular receptors [13,14]. Several neutralizing epitopes have been
mapped to ED III [15–17], indicating that ED III is a suitable target for
dengue vaccine development [18]. Recently, ED III subunit vaccine
candidates have been evaluated in mice [19–24] and nonhuman
primates [25–29]. In general, the immunogenicities of recombi-
nant subunit vaccines are poor, and adjuvants are necessary to
Open access under CC BY-NC-ND license.enhance immune responses. Unfortunately, aluminum-containing
adjuvants, which are the most widely used adjuvants in human vac-
cines, may  not be suitable for complete protection against dengue
viral infection [22,27,29].
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2.10. Statistical analysesC.-Y. Chiang et al. / Va
To overcome the obstacles associated with the low immuno-
enicity of recombinant proteins, we expressed high levels of
ecombinant protein in lipidated form to enhance the immuno-
enicity of the recombinant protein [30]. We  found that the lipid
oiety of the recombinant lipoprotein provided a danger signal
hat triggered antigen-presenting cell activation via toll-like recep-
or 2 [31]. Such activation further enhanced immune responses in
he absence of exogenous adjuvants [23,24,32]. Herein, we describe
he production of the recombinant lipidated dengue-4 envelope
rotein domain III (LD4ED III) and demonstrate its vaccine poten-
ial.
. Materials and methods
.1.  Virus
Dengue-4/H241 was  used for this study. Virus propagation was
erformed in C6/36 cells, and viral titers were determined by focus-
orming assays with BHK-21 cells [32,33].
.2. Preparation of recombinant proteins
The amino acid sequence of the dengue-4 envelope protein
omain III (D4ED III) was described previously [33]. Based on the
mino acid sequence of D4ED III, the DNA sequence was determined
ia Escherichia coli codon usage and was fully synthesized by a
iotechnology company (Purigo Biotechnology Co., Taipei, Taiwan).
he synthesized DNA was then ampliﬁed by PCR to generate pD4DE
II and pLD4DE III plasmids. E. coli BL21 (DE3) (Invitrogen, Carlsbad,
A) and C43(DE3) (Lucigen, Middleton, WI)  cells were transformed
ith pD4DE III and pLD4DE III cells to express D4ED III and LD4ED
II, respectively.
After isopropylthiogalactoside (IPTG) induction, recombinant
rotein was puriﬁed by immobilized metal afﬁnity chromatogra-
hy (IMAC) columns (QIAgen, Hilden, Germany). The fractions from
ach critical step were analyzed by SDS-PAGE and immunoblotted
ith anti-His-tag antibodies. The lipid moiety in LD4ED III was fur-
her identiﬁed by a MALDI micro MX  mass spectrometer (Waters,
anchester, UK). All the details of preparation of recombinant anti-
ens were in Supplementary data.
.3. Inhibition of dengue virus infection in BHK-21 cells by D4ED
II  and LD4ED III
To  test whether D4ED III and LD4ED III blocked dengue virus
nfection of BHK-21 cells, the virus was pre-mixed with different
mounts of D4ED III, heat-denatured D4ED III, LD4ED III, heat-
enatured LD4ED III, or control bovine serum albumin (BSA) as
ndicated for 10 min  at 4 ◦C. The viral titer prior to pre-mixing was
pproximately 20–40 FFUs per well. Viral adsorption was allowed
o proceed for 3 h at 37 ◦C. The FFUs were determined by focus-
orming assays.
.4.  Experimental mice and immunization
Female BALB/c mice were purchased from the National Lab-
ratory Animal Breeding and Research Center (Taipei, Taiwan).
he mice were maintained at the Laboratory Animal Center of the
ational Health Research Institutes (NHRI). All animal studies were
pproved and performed in compliance with the guidelines of the
nimal Committee of the NHRI. Groups of mice (6–8 weeks of age)
ere immunized subcutaneously with recombinant D4ED III or
D4ED III. The lyophilized D4ED III and LD4ED III were reconstituted
ith PBS. Each mouse received a 10 g/0.2-mL dose. Mice were
iven 2 immunizations at a 4-week interval with the same regi-
en. This immunization protocol was used throughout the present2 (2014) 1346–1353 1347
study.  Blood was collected by tail bleeding for 0.1–0.2 mL from each
mouse at different time points as indicated. Sera were prepared and
stored at −20 ◦C until use.
2.5.  Flow cytometry
To  determine the number of D4ED III-speciﬁc B cells, bone
marrow cells were collected at 3–4 weeks after the second
immunization. Single-cell suspensions were prepared for ﬂow
cytometry. Nonspeciﬁc staining was blocked by incubation with
a rat anti-mouse CD16/CD32 antibody (93, eBioscience) in PBS
for 10 min  at 4 ◦C. Cells were stained with phycoerythrin-cyanine
7-conjugated  anti-B220 (RA3-6B2, eBioscience), allophycocyanin-
conjugated anti-CD19 (1D3, BD Biosciences), and D4ED III. After
washing, cells were incubated with biotin-conjugated anti-His-
tag antibodies, and the D4ED III-bound cells were stained with
phycoerythrin-conjugated avidin (Sigma-Aldrich). The results were
acquired using the CellQuest Pro software on a BD FACSCalibur and
were analyzed using FACS 3 software.
2.6. Enzyme-linked immunospot (ELISPOT) assays
To detect and quantify individual anti-D4ED III antibody-
secreting B cells, bone marrow cells were analyzed by ELISPOT. All
the details were in Supplementary data.
2.7. Measurement of antibody titers
The levels of anti-D4ED III IgG in serum samples were deter-
mined by titration. All the details were in Supplementary data.
2.8.  Focus reduction neutralization tests (FRNT)
Sera were diluted using a 2-fold serial dilution (starting at
1:8), and the sera were heat-inactivated prior to testing. A
monolayer of BHK-21 cells in 24-well plates was inoculated
with dengue-4 virus that had been incubated at 4 ◦C overnight
with pre-immunization or post-immunization sera in a ﬁnal vol-
ume  of 0.5 mL.  The FFUs were determined by focus-forming
assays. The neutralizing antibody titer FRNT70 was  calculated
as the highest dilution that produced a 70% reduction in FFUs
compared with control samples containing the virus alone. For
calculation purposes, the neutralizing antibody titer was  desig-
nated as 4 when the neutralizing antibody titer was less than
8.
2.9. Challenge
Sixteen weeks after the second immunization, mice were
intraperitoneally injected with 5 × 107 dengue-4-infected K562
cells suspended in 0.5 mL  of serum-free RPMI medium [34]. Blood
samples were collected 8 h after K562 injection. The blood (0.2 mL)
was mixed with 0.02 mL  of 3.8% sodium citrate pre-chilled on ice.
Plasma was isolated, and the viral titer was determined by focus-
forming assays with BHK-21 cells. The detection limit of the assay
was 2.3 log10 FFU/mL. Any infective titers below the limit of detec-
tion were assigned a value of 2.0.Statistical  analyses were performed with ANOVA and a Bon-
ferroni post test using GraphPad Prism software version 5.02
(GraphPad Software, Inc.). Differences with a p-value of less than
0.05 were considered statistically signiﬁcant.
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Fig. 1. Cloning, production, and identiﬁcation of recombinant D4ED III and LD4ED III. (A) The amino acid sequence of D4ED III is a consensus sequence of dengue-4 [33]. The
DNA  sequence of D4ED III was  derived by codon usage of E. coli and was fully synthesized by a biotechnology company (see Section 2). The PCR product was cloned into
the  pET-22b(+) vector to generate the pD4ED III expression plasmid for the production of D4ED III. To produce lipidated D4ED III (LD4ED III), the pD4ED III construct was
cloned into the pET-22b(+) vector with a lipid signal peptide in front of the D4ED III gene to generate the pLD4ED III plasmid. Both recombinant proteins contained an
additional HHHHHH sequence (His-tag) at their C-termini and were expressed under the control of the T7 promoter. (B) The puriﬁcation processes of the D4ED III protein
were monitored using 15% reducing SDS-PAGE followed by Coomassie Blue staining and immunoblotting using anti-His-tag antibodies (lanes 1 to 8). D4ED III was expressed
in  E. coli strain BL21 (DE3). Lane 1, D4ED III expression after IPTG induction; lane 2, protein expression in the absence of IPTG induction; lane 3, soluble fraction of D4ED III;
lane  4, puriﬁed D4ED III. Lanes 5-8 show immunoblotting to monitor D4ED III induction and the puriﬁcation process; the samples in these lanes are the same as those in lanes
1–4.  The arrows indicate the electrophoretic positions of D4ED III in the gels or blots. The LD4ED III protein puriﬁcation process was monitored using 15% reducing SDS-PAGE
followed by Coomassie Blue staining and immunoblotting using anti-His-tag antibodies (lanes 9 to 16). LD4ED III was expressed in E. coli strain C43 (DE3). Lane 9, LD4ED III
expression after IPTG induction; lane 10, protein expression in the absence of IPTG induction; lane 11, soluble fraction of LD4ED III; lane 12, puriﬁed LD4ED III. Lanes 13–16
show  immunoblotting to monitor the LD4ED III induction and puriﬁcation processes. The samples in these lanes are the same as those in lanes 9–12. The arrows indicate
the electrophoretic positions of LD4ED III in the gels or blots. (C) N-terminal LD4ED III fragments were obtained and identiﬁed after digestion of LD4ED III with trypsin. The
tryptic  fragments of LD4ED III were analyzed on a Waters® MALDI micro MXTM mass spectrometer. The mass spectra revealed the existence of 3 major peaks with m/z values
of  1452, 1466, and 1480.
C.-Y. Chiang et al. / Vaccine 32 (2014) 1346–1353 1349
Fig. 2. Infection of dengue-4 virus is blocked by D4ED III and LD4ED III. Dengue-4 virus was pre-mixed with different amounts of bovine serum albumin, D4ED III, or LD4ED III
as  indicated for 10 min  at 4 ◦C. The heat-denatured protein was used in parallel experiments as controls. Viral adsorption on a monolayer of BHK-21 cells in 24-well plates
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. Results
.1. Preparation and characterization of dengue-4 envelope
rotein domain III recombinant antigens
The D4ED III gene was cloned into the pET-22b(+) expression
ector to produce the plasmids, pD4ED III and pLD4ED III, which
ere used for the production of the recombinant antigens, D4ED
II and LD4ED III, respectively. Both antigens contained an addi-
ional hexahistidine sequence (His-tag) at their C-termini and were
xpressed under the control of the T7 promoter (Fig. 1A). The puriﬁ-
ation of D4ED III and LD4ED III was monitored and analyzed by
DS-PAGE and immunoblotting (Fig. 1B). After removing LPS, the
esidual LPS in D4ED III and LD4ED III were less than 0.03 EU/g
nd 0.04 EU/g, respectively. The yields of D4ED III and LD4ED III
ere 75 mg/L and 10 mg/L, respectively. First, the exact mass of
rypsin-digested N-terminal fragments of LD4ED III was measured.
hree major peaks with m/z values of 1452, 1466, and 1480 were
dentiﬁed (Fig. 1C). These peaks have been previously identiﬁed as
 lipidation signature in other lipidated proteins [23,30,32].
It  has been demonstrated that dengue envelope protein domain
II is the critical site that is associated with binding to host cell
eceptors [13,14,22,23]. We  evaluated the ability of D4ED III and
D4ED III to hinder dengue viral infection. As shown in Fig. 2, the
nfection of BHK-21 cells with dengue-4 virus was blocked in the
resence of D4ED III in a dose-dependent manner compared with
ontrol bovine serum albumin. The ability of LD4ED III to inhibit
engue-4 viral infection was comparable to non-lipidated D4ED III.
n contrast, heat-denatured D4ED III and LD4ED III lost the capacity
o block dengue-4 viral infection. These results suggest that recom-
inant D4ED III and LD4ED III maintain the proper conformation
nd can compete with the dengue-4 virus for cellular binding sites.
.2. Evaluation of the humoral immune response against
engue-4 envelope protein domain III in mice
To determine the ability of the recombinant antigens to induce
4ED III-speciﬁc B cells, bone marrow cells were analyzed by ﬂow
ytometry (Fig. 3A). The percentage of D4ED III-speciﬁc B cells
n B220+ CD19+ bone marrow cells of D4ED III-immunized mice
as 0.05 ± 0.02%, which was equivalent to PBS-immunized micel infection. Data represent the mean ± SD of triplicate wells. The results shown are
 ANOVA with Bonferroni post test at the same dosage of bovine serum albumin. **
(0.03  ± 0.01%). In contrast, the percentage of D4ED III-speciﬁc B
cells in B220+ CD19+ bone marrow cells of LD4ED III-immunized
mice was  0.43 ± 0.11%, which was signiﬁcantly higher than that in
D4ED III- (p < 0.0001) and PBS-immunized mice (p < 0.0001). A rep-
resentative ﬂow cytometry staining panel gated on B220+CD19+
cells is shown in Fig. 3A (upper panel).
To quantify the frequencies of antibody-secreting cells,
total bone marrow cells were analyzed by ELISPOT (Fig. 3B).
The frequency of D4ED III-speciﬁc antibody-secreting cells in
PBS-immunized mice was 3.7 ± 2.7 cells per 105 cells. D4ED III-
immunized mice showed no increase in the frequency of D4ED
III-speciﬁc antibody-secreting cells (2.3 ± 1.6 cells per 105 cells).
However, a signiﬁcantly increased frequency of D4ED III-speciﬁc
antibody-secreting cells was  detected in LD4ED III-immunized
mice (24.6 ± 13.8 cells per 105 cells, p < 0.01). Representative
images of the B cell ELISPOT are shown in the upper panel of Fig. 3B.
We then evaluated the levels of D4ED III-speciﬁc antibodies in
the sera at different time points after immunization. As shown in
Fig. 4, the levels of D4ED III-speciﬁc antibodies in mice immunized
with D4ED III were comparable to those in control mice (PBS-
immunized). Importantly, the titers of D4ED III-speciﬁc antibodies
in LD4ED III-immunized mice were increased to 103.0–103.7 after
the priming vaccination. D4ED III-speciﬁc antibody titers were fur-
ther elevated after the boosting vaccination (range from 105.0 to
106.0) and were maintained for 20 weeks after the priming vaccina-
tion. These results indicate that LD4ED III induces higher antibody
responses than the non-lipidated D4ED III (p < 0.001).
3.3. Induction of durable protective immunity against dengue-4
virus  in mice
Because LD4ED III elicited D4ED III-speciﬁc antibody responses,
we next assessed the capacity of the antibodies to neutralize
dengue-4 virus. As shown in Fig. 5, no neutralizing antibody activi-
ties were observed in mice immunized with D4ED III or PBS (<1:8).
Interestingly, sera obtained from mice immunized with LD4ED III
induced low but signiﬁcant neutralizing antibody responses. The
neutralizing antibody titers peaked at 12 weeks after the priming
vaccination and were within the 1:8–1:16 dilutions.
The major objective of this study was to explore whether LD4ED
III could induce protective immunity. Mice are not the natural host
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Fig. 3. Identiﬁcation of D4ED III-speciﬁc B cells in the bone marrow of immunized mice.
BALB/c mice were immunized subcutaneously twice with 10 g of D4ED III (n = 5)
or LD4ED III (n = 5) in PBS at a 4-week interval. Mice immunized with PBS (n = 2–5)
alone (without antigens) served as controls. Bone marrow cells were harvested 7
weeks after the ﬁrst immunization. (A) CD19+B220+ B cells were gated, and the
expression  of the D4ED III-speciﬁc antibody was analyzed. The numbers indicate the
percentages of cells expressing D4ED III-speciﬁc antibody. A representative result
from each group is shown in the upper panel. The means and standard deviations
obtained  from different mice are shown in the lower panel. (B) D4ED III-speciﬁc
antibody-secreting cells were evaluated by ELISPOT. A representative well from each
group is shown in the upper panel. The means and standard deviations obtained from
different mice are shown in the lower panel. One of 2 representative experiments
is  shown. Statistical signiﬁcance was determined by ANOVA with Bonferroni post
test. ** p < 0.01; *** p < 0.0001.
Fig. 4. Humoral immune responses in mice immunized with vaccine candidates. BALB/c
mice were immunized subcutaneously twice with 10 g of D4ED III (n = 5) or LD4ED
III (n = 5) in PBS at a 4-week interval. Mice immunized with PBS (n = 3) alone (without
antigens) served as controls. Sera were collected from mice at the indicated time
points after the ﬁrst immunization. IgG antibodies against D4ED III were evaluated
by  ELISA. Pre-immune sera were collected and used to determine basal levels for
comparison. One of 2 representative experiments is shown. All antibody titers were
logarithmically transformed before statistical analyses. Statistical signiﬁcance was
determined by ANOVA with Bonferroni post test. * p < 0.001 compared with PBS. #
p < 0.001 compared with D4ED III.
of dengue virus. Dengue fever symptoms are not shown in mice
after dengue viral infection. Some immunodeﬁciency or immuno-
compromised mice are susceptible to dengue viral infection and
produce viremia. However, these animals are lack of a normal
immune response, making them inadequate for vaccine evalua-
tion. Yamanaka and Konishi [34] established a simple method for
evaluating dengue vaccine effectiveness in laboratory strains of
immunocompetent mice. To satisfy the requirement of validating
vaccine candidates, we adopted this method. Groups of BALB/c mice
were immunized with PBS, D4ED III or LD4ED III twice at a 4-week
interval. Twenty weeks after the ﬁrst immunization, the animals
were challenged with dengue-4-infected K562 cells. The protective
efﬁcacy results of LD4ED III as determined by the level of viremia are
shown in Fig. 6. The viral loads in the blood of D4ED III-immunized
mice were 103.4–103.8 FFU/mL, which were comparable to those
in PBS-immunized mice (103.0–103.6 FFU/mL). However, the viral
loads in the blood of LD4ED III-immunized mice were lower than
the detection limit, 102.3 FFU/mL. These results suggest that LD4ED
III elicits neutralizing antibody responses and inhibits viremia.
4.  Discussion
In the present study, we  prepared recombinant LD4ED III using a
novel E. coli-based system (Fig. 1) and evaluated the vaccine poten-
tial of LD4ED III. An important characteristic of adaptive immune
responses is the induction of durable protection after initial expo-
sure to a pathogen. Antibodies play a critical role in mediating
humoral immune protection. Upon antigen stimulation, naïve B
cells differentiate into antigen-speciﬁc B cells. Antibodies are then
produced by plasma cells. It is believed that long-lived plasma
cells migrate to the bone marrow. These bone marrow-resident
long-lived plasma cells are responsible for long-term humoral
immunity [35]. We  demonstrated that D4ED III-speciﬁc antibod-
ies were expressed on the surface of B cells in the bone marrow
at higher frequencies in LD4ED III-immunized mice than in D4ED
C.-Y. Chiang et al. / Vaccine 32 (2014) 1346–1353 1351
Fig. 5. Neutralizing antibody titers in mice immunized with vaccine candidates. BALB/c mice were immunized subcutaneously twice with 10 g of D4ED III (n = 5) or LD4ED III
(n  = 5) in PBS at a 4-week interval. Mice immunized with PBS (n = 3) alone (without antigens) served as controls. Sera were collected from mice at the indicated time points
after  the ﬁrst immunization. The dengue-4 virus neutralizing capacity was  determined by FRNT. The neutralizing antibody titer was calculated as the highest dilution that
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ere  logarithmically transformed before statistical analyses. Statistical signiﬁcance
II- or PBS-immunized mice (Fig. 3A). In addition, frequencies of
4ED III-speciﬁc antibody-secreting cells in the bone marrow of
D4ED III-immunized mice were higher than those in the bone mar-
ow of D4ED III- or PBS-immunized mice (Fig. 3B). These results
ndicate that B cell clones bearing D4ED III-speciﬁc antibodies with
ntibody secreting capacity resided in the bone marrow. Consis-
ent with these ﬁndings, we also showed that the D4ED III-speciﬁc
ntibody titers in the blood of LD4ED III-immunized mice were
aintained at high levels throughout the study (Fig. 4). These
ig. 6. Viremia in vaccinated mice after challenge with dengue-4 virus. BALB/c mice
ere immunized subcutaneously twice with 10 g of D4ED III (n = 5) or LD4ED
II  (n = 5) in PBS at a 4-week interval. Mice immunized with PBS alone (without
ntigens,  n = 3) served as controls. Sixteen weeks after the second immunization,
ice  were intraperitoneally challenged with dengue-4-infected K562 cells. The mice
ere bled 8 h after challenge. Plasma viral titers were determined by focus-forming
ssays  using BHK-21 cells. The detection limit of the assay was 2.3 log10 FFU/mL.
he  infective titers below the detection limit were assigned a value of 2.0. Sym-
ols  represent individual mice, and horizontal lines are the mean of experiments.
ne  of 2 representative experiments is shown. Viremia levels were logarithmically
ransformed  before statistical analyses. Statistical signiﬁcance was determined by
NOVA with Bonferroni post test. *** p < 0.0001.ne. One of 2 representative experiments is shown. The neutralizing antibody titers
etermined by ANOVA with Bonferroni post test. ** p < 0.01; *** p < 0.0001.
results suggest that D4ED III-speciﬁc long-lived plasma cells are
generated in LD4ED III-immunized mice.
Recombinant LD4ED III stimulates neutralizing antibodies with-
out exogenous adjuvant formulations (Fig. 5). These results are
in agreement with previous studies using recombinant lipidated
protein based on the envelope protein domain III. These studies
showed that lipidated protein induced memory [24] or long-
lasting neutralizing antibody [23,32] responses independently of
exogenous adjuvants. Although we  observed that the neutralizing
antibody titers in mice immunized with LD4ED III were modest
(Fig. 5), LD4ED III-immunized mice were efﬁciently able to suppress
viremia (Fig. 6). Viremia is an important factor in dengue disease
severity and transmission. Increased dengue disease severity cor-
relates with high viremia [36]. These results suggest that LD4ED III
elicits protective immunity.
In  our previous studies, we demonstrated that the performance
of lipidated antigens is superior or equivalent to non-lipidated anti-
gens formulated with alum [30] or PELC (a multiphase emulsion
system) [23]. To further illustrate the merit of lipidated antigens,
groups of mice were immunized subcutaneously with D4ED III,
D4ED III plus aluminum phosphate, or LD4ED III. Mice were given 3
immunizations at a 2-week interval. Serum samples were collected
at week 12. D4ED III speciﬁc IgG titers and dengue-4 virus neutraliz-
ing capacities were shown in the Supplementary ﬁgure. The D4ED
III speciﬁc IgG titers were signiﬁcantly enhanced in mice immu-
nized with the D4ED III plus aluminum phosphate. Importantly,
mice immunized with LD4ED III induced the highest antibody
responses among the other groups (Supplementary Fig. A). Notably,
the neutralizing antibody titers were detected in LD4ED III immu-
nized mice but not in mice immunized with D4ED III or D4ED
III plus aluminum phosphate (Supplementary Fig. B). Altogether,
these results demonstrate that the LD4ED III is better than that by
the D4ED III without or with aluminum phosphate.
It is very important for the LD4ED III to fold into the correct
conformation because some of the neutralizing epitopes in the
envelope protein domain III are conformation-dependent [37,38].
Notably, LD4ED III that retains the proper conformation will elicit
antibodies that recognize both linear and conformation-speciﬁc
epitopes. For this reason, an ideal subunit vaccine using envelope
protein domain III must be appropriately folded. In the present
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tudy, both D4ED III and LD4ED III formed the proper conforma-
ion necessary to block the cellular binding sites of dengue virus.
owever, the heat-denatured D4ED III and LD4ED III did not (Fig. 2).
hese results conﬁrm that lipidation of the dengue envelope pro-
ein domain III did not interfere with proper folding of the dengue
nvelope protein domain III [23].
The recombinant subunit dengue vaccine approach is dif-
erent than the live attenuated virus approach. Both of the
accine approaches have advantages and disadvantages. In gen-
ral, recombinant subunit dengue vaccine candidates are not very
mmunogenic. The administration of recombinant subunit dengue
accine candidates with modern adjuvants is required to obtain a
obust immune response [9]. However, the combination of adju-
ant and vaccine will increase the cost of the vaccination. The price
f a dengue vaccine is a key factor affecting the demand for dengue
accine [39,40]. The results of the current study provide tangible
vidence that LD4ED III induces protective immunity without the
eed for adjuvants in mice. Therefore, the cost of LD4ED III vaccina-
ion will be reduced, and the potential barrier of including dengue
accines in national immunization programs will be reduced.
.  Conclusions
We  demonstrated that LD4ED III expressed in E. coli retains the
roper conformation to compete with dengue virus for cellular
inding sites. We  showed that LD4ED III is more immunogenic than
ts nonlipidated counterpart, D4ED III. Most importantly, LD4ED
II alone triggered a neutralizing antibody response and inhibited
iremia in immunized mice. These results provide important infor-
ation for future clinical studies of the LD4ED III subunit vaccine.
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